by Katie Hogan | Jun 18, 2026 | Oncology
As we head to Chicago for ASCO 2026, the most critical questions go beyond which trials met their primary endpoints. They are about what happens next in the clinic, in the market, and in the minds of the physicians who must translate this data into practice. Here are...
by Katie Hogan | Apr 29, 2026 | Oncology
Why an Oncology CoE? Because Complexity Has Outpaced Human Capacity. A widening synthesis gap – the distance between the overwhelming volume of clinical data and a team’s ability to translate it into a winning strategy – is the real challenge in oncology...
by Katie Hogan | Mar 26, 2026 | Oncology
For decades, oncology has pursued the ‘magic bullet,’ precision therapies that selectively eradicate tumors while sparing healthy tissue. Antibody-drug conjugates (ADCs) are among the closest realizations of that vision. Yet as the pipeline saturates, a new...
